These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 19036704)

  • 21. AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia.
    Zhou F; Liu Y; Rohde C; Pauli C; Gerloff D; Köhn M; Misiak D; Bäumer N; Cui C; Göllner S; Oellerich T; Serve H; Garcia-Cuellar MP; Slany R; Maciejewski JP; Przychodzen B; Seliger B; Klein HU; Bartenhagen C; Berdel WE; Dugas M; Taketo MM; Farouq D; Schwartz S; Regev A; Hébert J; Sauvageau G; Pabst C; Hüttelmaier S; Müller-Tidow C
    Nat Cell Biol; 2017 Jul; 19(7):844-855. PubMed ID: 28650479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NHR4 domain mutations of ETO are probably very infrequent in AML1-ETO positive myeloid leukemia cells.
    Hackanson B; Abdelkarim M; Jansen JH; Lübbert M
    Leukemia; 2010 Apr; 24(4):860-1. PubMed ID: 20090777
    [No Abstract]   [Full Text] [Related]  

  • 23. The AML1/ETO(MTG8) and AML1/Evi-1 leukemia-associated chimeric oncoproteins accumulate PEBP2beta(CBFbeta) in the nucleus more efficiently than wild-type AML1.
    Tanaka K; Tanaka T; Kurokawa M; Imai Y; Ogawa S; Mitani K; Yazaki Y; Hirai H
    Blood; 1998 Mar; 91(5):1688-99. PubMed ID: 9473235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inability of RUNX1/AML1 to breach AML1-ETO block of embryonic stem cell definitive hematopoiesis.
    Peterson LF; Lo MC; Okumura AJ; Zhang DE
    Blood Cells Mol Dis; 2007; 39(3):321-8. PubMed ID: 17692541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 26. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1.
    Nishida S; Hosen N; Shirakata T; Kanato K; Yanagihara M; Nakatsuka S; Hoshida Y; Nakazawa T; Harada Y; Tatsumi N; Tsuboi A; Kawakami M; Oka Y; Oji Y; Aozasa K; Kawase I; Sugiyama H
    Blood; 2006 Apr; 107(8):3303-12. PubMed ID: 16380455
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ETO and AML1 phosphoproteins are expressed in CD34+ hematopoietic progenitors: implications for t(8;21) leukemogenesis and monitoring residual disease.
    Erickson PF; Dessev G; Lasher RS; Philips G; Robinson M; Drabkin HA
    Blood; 1996 Sep; 88(5):1813-23. PubMed ID: 8781439
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple subnuclear targeting signals of the leukemia-related AML1/ETO and ETO repressor proteins.
    Barseguian K; Lutterbach B; Hiebert SW; Nickerson J; Lian JB; Stein JL; van Wijnen AJ; Stein GS
    Proc Natl Acad Sci U S A; 2002 Nov; 99(24):15434-9. PubMed ID: 12427969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leukemogenic AML1-ETO fusion protein increases carcinogen-DNA adduct formation with upregulated expression of cytochrome P450-1A1 gene.
    Xu M; Li D; Lu Y; Chen GQ
    Exp Hematol; 2007 Aug; 35(8):1249-55. PubMed ID: 17560011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Junctions of the AML1/MTG8(ETO) fusion are constant in t(8;21) acute myeloid leukemia detected by reverse transcription polymerase chain reaction.
    Kozu T; Miyoshi H; Shimizu K; Maseki N; Kaneko Y; Asou H; Kamada N; Ohki M
    Blood; 1993 Aug; 82(4):1270-6. PubMed ID: 8353289
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular targeting of aberrant transcription factors in leukemia: strategies for RUNX1/ETO.
    Wichmann C; Grez M; Lausen J
    Curr Drug Targets; 2010 Sep; 11(9):1181-91. PubMed ID: 20583973
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Expression of AML1/ETO9a isoform in acute myeloid leukemia-M2 subtype].
    Miao YQ; Chen ZX; He J; Cen JN; Bao XJ; Qiu QC; Zhang DE; Yan M
    Zhonghua Xue Ye Xue Za Zhi; 2007 Jan; 28(1):27-9. PubMed ID: 17649722
    [TBL] [Abstract][Full Text] [Related]  

  • 34. AML1-MTG8 leukemic protein induces the expression of granulocyte colony-stimulating factor (G-CSF) receptor through the up-regulation of CCAAT/enhancer binding protein epsilon.
    Shimizu K; Kitabayashi I; Kamada N; Abe T; Maseki N; Suzukawa K; Ohki M
    Blood; 2000 Jul; 96(1):288-96. PubMed ID: 10891464
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AML1-ETO targets and suppresses cathepsin G, a serine protease, which is able to degrade AML1-ETO in t(8;21) acute myeloid leukemia.
    Jin W; Wu K; Li YZ; Yang WT; Zou B; Zhang F; Zhang J; Wang KK
    Oncogene; 2013 Apr; 32(15):1978-87. PubMed ID: 22641217
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
    Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes.
    Bakshi R; Zaidi SK; Pande S; Hassan MQ; Young DW; Montecino M; Lian JB; van Wijnen AJ; Stein JL; Stein GS
    J Cell Sci; 2008 Dec; 121(Pt 23):3981-90. PubMed ID: 19001502
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell type dependent regulation of multidrug resistance-1 gene expression by AML1-ETO.
    Hines R; Boyapati A; Zhang DE
    Blood Cells Mol Dis; 2007; 39(3):297-306. PubMed ID: 17590361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chaperonin TRiC/CCT Modulates the Folding and Activity of Leukemogenic Fusion Oncoprotein AML1-ETO.
    Roh SH; Kasembeli M; Galaz-Montoya JG; Trnka M; Lau WC; Burlingame A; Chiu W; Tweardy DJ
    J Biol Chem; 2016 Feb; 291(9):4732-41. PubMed ID: 26706127
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The 8;21 translocation in leukemogenesis.
    Peterson LF; Zhang DE
    Oncogene; 2004 May; 23(24):4255-62. PubMed ID: 15156181
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.